Repeatability of exhaled nitric oxide measurements in patients with COPD

Clinical Physiology and Functional Imaging

Volumn 31, Issue 1, 2011, Pages 26-31

  Rouhos, Annamari ^a   Kainu, Annette ^a   Piirilä, Päivi ^a   Sarna, Seppo ^b   Lindqvist, Ari ^a   Karjalainen, Jouko ^a,c   Sovijärvi, Anssi R A ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c CENTRAL MILITARY HOSPITAL   (Finland)

Author keywords

Chronic obstructive pulmonary disease; Eosinophilic inflammation; Fixed bronchial obstruction; Fractional exhaled nitric oxide; Reproducibility

Indexed keywords

FRACTIONAL EXHALED NITRIC OXIDE; NITRIC OXIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; EXHALATION; FEMALE; FLOW RATE; FRACTIONAL EXHALED NITRIC OXIDE MEASUREMENT; HUMAN; LUNG FUNCTION TEST; MALE; MEASUREMENT; PRIORITY JOURNAL; REPEAT PROCEDURE; SPIROMETRY;

ADULT; AGED; ASTHMA; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; EXHALATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EOSINOPHILIA; SPIROMETRY; STEROIDS; YOUNG ADULT;

EID: 78650130534     PISSN: 14750961     EISSN: 1475097X     Source Type: Journal    
DOI: 10.1111/j.1475-097X.2010.00975.x     Document Type: Article

References (32)

1. ATS/ERS recommendations for standardized procedures for the online and offline measurements of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med (2005); 171: 912-930.
2. Barnes PJ, Chowdhury B, Kharitonov SA, Magnussen H, Page CP, Postma D, Saetta M. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006); 174: 6-14.
3. Bhowmik A, Seemungal TAR, Donaldson GC, Wedzicha JA. Effects of exacerbations and seasonality on exhaled nitric oxide in COPD. Eur Respir J (2005); 26: 1009-1015.
4. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet (1986); 1: 307-310.
5. Bohadana A, Michealy J-P, Teculescu D, Wild P. Reproducibility of exhaled nitric oxide in smokers and non-smokers: relevance for longitudinal studies. BMC Pulm Med (2008); 8: 4.
6. Brightling CE, Monteiro W, Ward R, Parker D, Morgan MDL, Wardlaw AJ, Pavrod ID. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (2000); 356: 1480-1485.
7. Brightling CE, McKenna S, Hargadon B, Birring S, Green R, Siva R, Berry M, Parker D, Monteiro W, Pavrod ID, Bradding P. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax (2005); 60: 193-198.
8. Brindicci C, Ito K, Resta O, Pride N, Barnes PJ, Kharitonov SA. Exhaled nitric oxide from lung periphery is increased in COPD. Eur Respir J (2005); 26: 52-59.
9. Chinn S. Repeatability and method comparison. Statistics in respiratory medicine. Thorax (1991); 46: 454-456.
10. Ekroos H, Tuominen J, Sovijärvi ARA. Exhaled nitric oxide and its long-term variation in healthy non-smoking subjects. Clin Physiol (2000); 20: 434-439.
11. Ekroos H, Karjalainen J, Sarna S, Laitinen LA, Sovijärvi ARA. Short-term variability of exhaled nitric oxide in young male patients with mild asthma and in healthy subjects. Respir Med (2002); 96: 895-900.
12. Fabbri LM, Romagnoli M, Corbetta L, Casoni G, Busljetic K, Turato G, Ligabue G, Ciaccia A, Saetta M, Papi A. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2003); 167: 418-424.
13. Faul JL, Demers EA, Burke CM, Poulter LW. The reproducibility of repeat measures af airway inflammation in stable atopic asthma. Am J Respir Crit Care Med (1999); 160: 1457-1461.
14. Kharitonov SA, Gonio F, Kelly C, Meah S, Barnes PJ. Reproducibility of exhaled nitric oxide measurements in healthy and asthmatic adults and children. Eur Respir J (2003); 21: 433-438.
15. Kunisaki KM, Rice KL, Janoff EN, Rector TS, Niewoehner DE. Exhaled nitric oxide, systemic inflammation, and spirometric response to inhaled fluticasone propionate in severe chronic obstructive pulmonary disease: a prospective study. Ther Adv Respir Dis (2008); 2: 55-64.
16. De Laurentiis G, Maniscalco M, Cianciulli F, Stanziola A, Marisco S, Lundberg JO, Weitzberg E, Sofia M. Exhaled nitric oxide monitoring in COPD using a portable analyzer. Pulm Pharmacol Ther (2008); 21: 689-693.
17. Lehtimäki L, Kankaanranta H, Saarelainen S, Annila I, Nieminen R, Moilanen E. Bronchial nitric oxide is related to symptom relief during fluticasone treatment in COPD. Eur Respir J (2010); 35: 72-78.
18. Leigh R, Pizzichini MMM, Morris MM, Maltais F, Hargreave FE, Pizzichini E. Stable COPD: predicting benefit from hig-dose inhaled corticosteroid treatment. Eur Respir J (2006); 27: 964-971.
19. Marteus H, Törnberg DC, Weitzberg E, Schedin U, Alving K. Origin of nitrite and nitrate in nasal and exhaled breath condensate and relation to nitric oxide formation. Thorax (2005); 60: 219-225.
20. McGraw KO, Wong SP. Forming inferences about some intraclass correlation coefficients. Psychol Methods (1996); 1: 30-46.
21. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, Van Der Grinten CPM, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J. Standardisation of spirometry. Eur Respir J (2005); 26: 319-338.
22. Papi A, Romagnoli M, Baraldo S, Braccioni F, Guzzinati I, Saetta M, Ciaccia A, Fabbri LM. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive oulmonary disease. Am J Respir Crit Care Med (2000); 162: 1773-1777.
23. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, Van Der Grinten CPM, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J. Interpretative strategies for lung function tests. Eur Respir J (2005); 26: 948-968.
24. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, Van Weel C, Zielinski J. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. GOLD Executive Summary. Am J Respir Crit Care Med (2007); 176: 532-555.
25. Rouhos A, Kainu A, Karjalainen J, Lindqvist A, Piirilä P, Sarna S, Haahtela T, Sovijärvi ARA. Atopic sensitization to common allergens without symptoms or signs of airway disorders does not increase exhaled nitric oxide. Clin Respir J (2008); 2: 141-148.
26. Shrout PE, Fleiss JK. Intraclass correlations: uses in assessing reliability. Psychol Bull (1979); 86: 420-428.
27. Silkoff PE, Wakita S, Chatkin J, Ansarin K, Gutierrez C, Caramori M, McClean P, Slutsky S, Zamal N, Chapman KR. Exhaled nitric oxide after b2-agonist inhalation and spirometry in asthma. Am J Respir Crit Care Med (1999); 159: 940-944.
28. Sutherland ER, Martin RJ. Airway inflammation in chronic obstructive pulmonary disease: comparisons with asthma. J Allergy Clin Immunol (2003); 112: 819-827.
29. Taylor DR, Pijnenburg MW, Smith AD, De Jongste JC. Exhaled nitric oxide measurements: clinical application and interpretation. Thorax (2006); 61: 817-827.
30. Viljanen AA, Halttunen PK, Kreus K-E, Viljanen BC. Spirometric studies in non-smoking, healthy adults. Scand J Clin Lab Invest Suppl (1982); 159: 5-20.
31. Zetterquist W, Pedroletti C, Lundberg JON, Alving K. Salivary contribution to exhaled nitric oxide. Eur Respir J (1999); 13: 327-333.
32. Zietkowski Z, Kucharewicz I, Bodzenta-Lukaszyk A. The influence of inhaled corticosteroids on exhaled nitric oxide in stable chronic obstructive disease. Respir Med (2005); 99: 816-824.